Advanced Viral Research initiates Phase IIb wound healing trial

The Phase IIb trial is being conducted at the Friedrich Alexander University Hospital in Erlangen, Germany, led by Eckhart Kampgen, associate professor for strategies of cellular immunotherapy at the department of dermatology.

The primary objective of this study is to evaluate the effect of AVR123, applied topically, on the rate and quality of healing of wounds. According to the protocol, patients enrolled in the study will include individuals with a variety of wounds and dermatologic conditions.

AVR123 is a topical formulation of ARV118 which is currently being investigated for the systemic treatment of cancer related clinical cachexia. According to the company, this compound has well-documented anti-inflammatory and wound healing activities.

In tandem with the commencement of this trial, the company has received the third installment worth $249,500 as financing from Yorkville Capital partners.

Stephen Elliston, president and CEO of Advanced Viral, said: “This trial has been designed to provide further evidence to substantiate encouraging preliminary results seen in the initial phase of the study, which was not completed due to the death of the study’s principal investigator. We are highly fortunate to have Dr Kampgen to oversee this trial. His experience in this area will be invaluable for gaining greater insights into AVR123’s potential efficacy.”